You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 9,901,556


✉ Email this page to a colleague

« Back to Dashboard


Title:Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Abstract: Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
Inventor(s): Graeber; Michael (Lawrenceville, NJ), Czernielewski; Janusz (Biot, FR)
Assignee: GALDERMA RESEARCH & DEVELOPMENT (Biot, FR)
Filing Date:Jun 16, 2016
Application Number:15/184,262
Claims:1. A method for eliciting an early onset of action in regression of inflammatory lesions, regression of non-inflammatory lesions or regression of total acne lesions in treating common acne afflicting an individual's skin, the individual being in need of such treatment, comprising topically administering daily to said individual an anti-acne effective amount of a pharmaceutical composition which comprises: (1) 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid (adapalene) or salt thereof; (2) one or more ingredients selected from the group consisting of carbomer 940, carbomer 934, PEG methyl glucose sesquistearate, PEG 400, methyl glucose sesquistearate, cyclomethicone, perhydrosqualene, glycerol, and phenoxyethanol; (3) water; and (4) at least one additive selected from the group consisting of a chelating agent, a preservative, a wetting agent, a pH regultor, an osmotic pressure modifier, an emulsifier, a UV-A screening agent, a UV-B screening agent; a propyl paraben, and an antioxidant; wherein said composition is formulated into a pharmaceutically acceptable medium therefor, said composition being a gel or a cream, wherein said early onset of action occurs by four weeks after treatment begins and is demonstrated by regression of inflammatory lesions, regression of non-inflammatory lesions or regression of total acne lesions after four weeks of treatment greater than that demonstrated by vehicle alone or by a similar composition comprising 0.1% by weight of adapalene after four weeks of treatment.

2. The method according to claim 1, wherein the common acne is of moderate to moderately severe intensity.

3. The method according to claim 1, wherein the composition is a gel comprising adapalene, carbomer 940, disodium edetate, methyl paraben, poloxamer 124, propylene glycol, sodium hydroxide and purified water.

4. The method according to claim 1, wherein the composition is a gel comprising adapalene, carbomer 934, disodium edetate, PEG methyl glucose sesquistearate, methyl glucose sesquistearate, glycerol, methyl paraben, cyclomethicone, perhydrosqualene, phenoxyethanol, propyl paraben, sodium hydroxide and purified water.

5. The method according to claim 1, wherein the composition is a gel comprising adapalene, PEG 400 and ethanol.

6. A method for eliciting an early onset of action in regression of inflammatory lesions in treating common acne afflicting an individual's skin, the individual being in need of such treatment, comprising topically administering daily to said individual an anti-acne effective amount of a pharmaceutical composition which comprises: (1) 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid (adapalene) or salt thereof; (2) one or more ingredients selected from the group consisting of carbomer 940, carbomer 934, PEG methyl glucose sesquistearate, PEG 400, methyl glucose sesguistearate, cyclomethicone, perhydrosqualene, glycerol, and phenoxyethanol; (3) water; and (4) at least one additive selected from the group consisting of a chelating agent, a preservative, a wetting agent, a pH regulator, an osmotic pressure modifier, an emulsifier, a UV-A screening agent, a UV-B screening agent, a propyl paraben, and an antioxidant; wherein said compositon is formulated into a pharmaceutically acceptable medium therefor, said composition being a gel or a cream, wherein said early onset of action occurs by four weeks after treatment begins and is demonstrated by regression of inflammatory lesions after four weeks of treatment greater than that demonstrated by vehicle alone or by a similar composition comprising 0.1% by weight of adapalene after four weeks of treatment.

7. The method according to claim 6, wherein the common acne is of moderate to moderately severe intensity.

8. The method according to claim 6, wherein the composition is a gel comprising adapalene, carbomer 940, disodium edetate, methyl paraben, poloxamer 124, propylene glycol, sodium hydroxide and purified water.

9. The method according to claim 6, wherein the composition is a gel comprising adapalene, carbomer 934, disodium edetate, PEG methyl glucose sesquistearate, methyl glucose sesquistearate, glycerol, methyl paraben, cyclomethicone, perhydrosqualene, phenoxyethanol, propyl paraben, sodium hydroxide and purified water.

10. The method according to claim 6, wherein the composition is a gel comprising adapalene, PEG 400 and ethanol.

11. A method for eliciting en early onset of action in regression of non-inflammatory lesions in treating common acne afflicting an individual's skin, the individual being in need of such treatment, comprising topically administering daily to said individual an anti-acne effective amount of a pharmaceutical composition which comprises: (1) 0.3% by weight of 6-[3-(1-adamantyl)-4-metaoxyphenyl]-2-naphthoic acid (adapalene) or salt thereof; (2) one or more ingredients selected from the group consisting of carbomer 940, carbomer 934, PEG methyl glucose sesquistearate, PEG 400, methyl glucose sesquistearate, cyclomethicone, perhydrosqualene, glycerol, and phenoxyethanol; (3) water; and (4) at least one additive selected from the group consisting of a chelating agent, a preservative, a wetting agent, a pH regulator, an osmotic pressure modifier, an emulsifier, a UV-A screening agent, a UV-B screening agent, a propyl paraben, and an antioxidant; wherein said composition is formulated into a pharmaceutically acceptable medium therefor, said composition being a gel or a cream, said early onset of action occurring by four weeks after treatment begins and being demonstrated by regression of non-inflammatory lesions after four weeks of treatment greater than that demonstrated by vehicle alone or by a similar composition comprising 0.1% by weight of adapalene after four weeks of treatment.

12. The method according to claim 11, wherein the common acne is of moderate to moderately severe intensity.

13. The method according to claim 11, wherein the composition is a gel comprising adapalene, carbomer 940, disodium edetate, methyl paraben, poloxamer 124 propylene glycol, sodium hyrdoxide and purified water.

14. The method according to claim 11, wherein the composition is a gel comprising adapalene, carbomer 934, disodium edetate, PEG methyl glucose sesquistearate, methyl glucose sesquistearate, glycerol, methyl paraben, cyclomethicone, perhydrosqualene, phenoxyethanol, propyl paraben, sodium hydroxide and purified water.

15. The method according to claim 11, wherein the composition is a gel comprising adapalene, PEG 400 and ethanol.

16. A method for eliciting an early onset of action in regression of total acne lesions in treating common acne afflicting an individual's skin, the individual being in need of such treatment, comprising topically administering daily to said individual an anti-acne effective amount of a pharmaceutical composition which comprises: (1) 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid (adapalene) or salt thereof; (2) one or more ingredients selected from the group consisting of carbomer 940, carbomer 934,PEG methyl glucose sesquistearate, PEG 400, methyl glucose sesquistearate, cyclomethicone, perhydrosqualene, glycerol, and phenoxyethanol; (3) water; and (4) at least one additive selected from the group consisting of a chelating agent, a preservative, a wetting agent, a pH regulator, an osmotic pressure modifier, an emulsifier, a UV-A screening agent, a UV-B screening agent, a propyl paraben, and an antioxidant; wherein said composition is formulated into a pharmaceutically acceptable medium therefor, said composition being a gel or a cream, said early onset of action occurring by four weeks after treatment begins and being demonstrated by regression of total acne lesions after four weeks of treatment greater than that demonstrated by vehicle alone or by a similar composition comprising 0.1% by weight of adapalene after four weeks of treatment.

17. The method according to claim 16, wherein the common acne is of moderate to moderately severe intensity.

18. The method according to claim 16, wherein the composition is a gel comprising adapalene, carbomer 940, disodium edetate, methyl paraben, poloxamer 124 propylene glycol, sodium hydroxide and purified water.

19. The method according to claim 16, wherein the composition is a gel comprising adapalene, carbomer 934, disodium edetate, PEG methyl glucose sesquistearate, methyl glucose sesquistearate, glycerol, methyl paraben, cyclomethicone, perhydrosqualene, phenoxyethanol, propyl paraben, sodium hydroxide and purified water.

20. The method according to claim 16, wherein the composition is a gel comprising adapalene, PEG 400 and ethanol.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.